InMed Pharmaceuticals

(NASDAQ) INM

Current Price$1.54

Market Cap$5.00M

Since IPO (2014)-100%

5 Year-100%

1 Year-55%

1 Month-7%

InMed Pharmaceuticals Financials at a Glance

Market Cap

$5.00M

Revenue (TTM)

$4.02M

Net Income (TTM)

-$9.91M

EPS (TTM)

-$2.58

P/E Ratio

-0.59

Dividend

$0.00

Beta (Volatility)

1.29 (Average)

Dividend

$0.00

Beta (Volatility)

1.29 (Average)

Price

$1.54

Volume

71,283

Open

$1.58

Price

$1.54

Volume

71,283

Open

$1.58

Previous Close

$1.54

Daily Range

$1.49 - $1.59

52-Week Range

$0.58 - $3.55

Estimated Earnings Date

Sep 18, 2026

Dividend

$0.00

Beta (Volatility)

1.29 (Average)

Price

$1.54

Volume

71,283

Open

$1.58

Previous Close

$1.54

Daily Range

$1.49 - $1.59

52-Week Range

$0.58 - $3.55

Estimated Earnings Date

Sep 18, 2026

INM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About InMed Pharmaceuticals

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Eric A. Adams

Website

www.inmedpharma.com

Headquarters

Vancouver, BC V6C 1B4, CA

INM Financials

Key Financial Metrics (TTM)

Gross Margin

30.44%

Operating Margin

-246.78%

Net Income Margin

-246.41%

Return on Equity

-72.72%

Return on Capital

-41.00%

Return on Assets

-108.52%

Earnings Yield

-1.69%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.00M

Shares Outstanding

3.31M

Volume

71.28K

Avg. Volume

1.63M

Financials (TTM)

Gross Profit

$1.22M

Operating Income

-$9.93M

EBITDA

-$9.23M

Operating Cash Flow

-$9.01M

Capital Expenditure

$9.49

Free Cash Flow

-$9.01M

Cash & ST Invst.

$5.20M

Total Debt

$420.15K

InMed Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$5.00M

N/A

Market Cap/Employee

$384.94K

N/A

Employees

N/A

Net Income

-$2.97M

-39.9%

EBITDA

-$2.66M

-33.5%

Quarterly Fundamentals

Name

Q3 2026YOY CHG

Total Cash

$5.20M

-22.0%

Total Debt

$420.15K

-65.2%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

-100.0%

Long Term Debt

$30.77K

-94.8%

Short Term Debt

$389.38K

-36.3%

Return on Assets

-1.09%

N/A

Return on Invested Capital

-1.43%

N/A

Free Cash Flow

-$1.76M

-6.0%

Operating Cash Flow

-$1.76M

-6.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SILOSilo Pharma, Inc.

SILOSilo Pharma, Inc.$6.05+4.68%

GLMDGalmed Pharmaceuticals Ltd.

GLMDGalmed Pharmaceuticals Ltd.$0.57+0.00%

CNSPCNS Pharmaceuticals, Inc.

CNSPCNS Pharmaceuticals, Inc.$3.98-4.14%

BDRXBiodexa Pharmaceuticals Plc

BDRXBiodexa Pharmaceuticals Plc$2.92+16.80%

GNPXGenprex, Inc.

GNPXGenprex, Inc.$0.49+5.03%

JAGXJaguar Health, Inc.

JAGXJaguar Health, Inc.$3.01+10.26%

GRIGRI Bio, Inc.

GRIGRI Bio, Inc.$1.82-8.08%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$17.87+0.02%

ONDSOndas

ONDSOndas$7.83+0.02%

HLHecla Mining

HLHecla Mining$15.54+0.03%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.67+0.04%

TAT&T

TAT&T$22.72+0.01%

NWLNewell Brands

NWLNewell Brands$5.82-0.01%

WENWendy's

WENWendy's$7.80+0.06%

Questions About INM

What is the current price of InMed Pharmaceuticals?

InMed Pharmaceuticals is trading at $1.54 per share.

What is the 52-week range for InMed Pharmaceuticals?

Over the past 52 weeks, InMed Pharmaceuticals has traded between $0.58 and $3.55.

How much debt does InMed Pharmaceuticals have?

As of the most recent reporting period, InMed Pharmaceuticals reported total debt of $420.15K.

How much cash does InMed Pharmaceuticals have on hand?

InMed Pharmaceuticals reported $5.16M in cash and cash equivalents in its most recent financial results.

What is InMed Pharmaceuticals’s dividend yield?

InMed Pharmaceuticals does not currently have a dividend yield.

InMed Pharmaceuticals

InMed Pharmaceuticals Financials at a Glance

INM News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About InMed Pharmaceuticals

INM Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

InMed Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About INM

What is the current price of InMed Pharmaceuticals?

What is the 52-week range for InMed Pharmaceuticals?

How much debt does InMed Pharmaceuticals have?

How much cash does InMed Pharmaceuticals have on hand?

What is InMed Pharmaceuticals’s dividend yield?

Premium Investing Services